{"id":"NCT01059799","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","officialTitle":"A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGINâ„¢: ONCE ASIA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-01","primaryCompletion":"2010-12-16","completion":"2010-12-16","firstPosted":"2010-02-01","resultsPosted":"2015-11-13","lastUpdate":"2017-03-30"},"enrollment":435,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDeg OD","type":"EXPERIMENTAL"},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with insulin.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDeg OD","deltaMin":-1.24,"sd":0.87},{"arm":"IGlar OD","deltaMin":-1.35,"sd":0.87}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":53,"countries":["Hong Kong","Japan","Malaysia","South Korea","Taiwan","Thailand"]},"refs":{"pmids":["26121451","23130654","26484727","24170235","26232910","26663320","25081590","24812526","24843715"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":284},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diabetic retinopathy"]}}